Evotec SE (Nasdaq: here) is One of the 10 best Penny shares in health care to buy according to analysts. On June 25, the company said that it would participate in the Nurture-Aki consortium to investigate acute kidney injury (AKI) and to develop drug discovery through approaches with several OMics.
A research team in laboratory jackets that test a new immunophagus platform in a modern biotechnology laboratory.
The Nurture-Aki consortium aims to set up the largest cohort database of the patient for AKI with dual objectives: improve the understanding of its molecular mechanisms and accelerate the discovery of medicines. The consortium is supported by £ 4.7 million from industrial partners, including Evotec, AstraZeneca (Nasdaq: AZN) and Nephrolyx GmbH, facilitated by Nier Research UK. Professor Nick Selby, an important researcher, supervises the AKI investigation efforts within the Nurture Initiative.
In addition to helping financing the consortium, Evotec integrates the data of the consortium in its own E.MPD platform. The company will also perform state-of-the-art omics analyzes to identify core biological mechanisms, molecular goals and biomarkers for AKI. Ultimately, the Evotec partnership enables to perform targeted medicine discovery by using molecular insights in the progression of AKI.
Evotec SE (Nasdaq: EVO) is a German biotechnology company. It works as a partner for discovering medicines and development for pharmaceutical and biotech companies worldwide. The two main segments are shared R&D, which offers integrated research services, and Just -Votec Biologics, which offers organic development and production.
Although we recognize the potential of EVO as an investment, we believe that certain AI shares offer greater upward potential and bring down fewer risks. If you are looking for an extremely undervalued AI shares that also benefits considerably from rates from the Trump era and the Onshoring trend, see our free report on the Best AI shares in the short term.
Read next: Goldman Sachs Energy Stocks: 10 shares to buy And 10 best AI shares to buy according to billionaire David Tepper.
Publication: none.
